ZIVO Bioscience to Deregister Securities and Cease SEC Public Reporting

ZIVO Bioscience (ZIVO) has announced its intention to deregister its securities with the U.S. Securities and Exchange Commission (SEC). As part of this transition, the company will cease its public financial reporting and stop complying with ongoing disclosure requirements. The Board of Directors described the move as a carefully considered strategic decision for the firm's future operations. This shift is likely intended to reduce the significant regulatory costs and administrative burdens associated with maintaining SEC compliance. However, the move to stop public reporting typically results in reduced liquidity and transparency for current shareholders. Market analysts suggest that such transitions often lead to a decline in investor confidence and increased share price volatility in the over-the-counter markets.

Sources:businesswire.comstocktitan.netbarchart.com